首页> 美国卫生研究院文献>World Journal of Gastroenterology >Oral administration of S-nitroso-N-acetylcysteine prevents the onset of non alcoholic fatty liver disease in rats
【2h】

Oral administration of S-nitroso-N-acetylcysteine prevents the onset of non alcoholic fatty liver disease in rats

机译:口服S-亚硝基-N-乙酰半胱氨酸可预防大鼠非酒精性脂肪肝的发作

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To evaluate the potential of S-nitroso-N-acetylcysteine (SNAC) in inhibition of lipid peroxidation and the effect of oral SNAC administration in the prevention of nonalcoholic fatty liver disease (NAFLD) in an animal model.METHODS: NAFLD was induced in Wistar male rats by choline-deficient diet for 4 wk. SNAC-treated animals (n=6) (1.4 mg/kg/day of SNAC, orally) were compared to 2 control groups: one (n=6) received PBS solution and the other (n=6) received NAC solution (7 mg/kg/d). Histological variables were semiquantitated with respect to macro and microvacuolar fat changes, its zonal distribution, foci of necrosis, portal and perivenular fibrosis, and inflammatory infiltrate with zonal distribution. LOOHs from samples of liver homogenates were quantified by HPLC. Nitrate levels in plasma of portal vein were assessed by chemiluminescence. Aqueous low-density lipoprotein (LDL) suspensions (200 µg protein/mL) were incubated with CuCl2 (300 µmol/L) in the absence and presence of SNAC (300 µmol/L) for 15 h at 37 °C. Extent of LDL oxidation was assessed by fluorimetry. Linoleic acid (LA) (18.8 µmol/L) oxidation was induced by soybean lipoxygenase (SLO) (0.056 µmol/L) at 37 °C in the presence and absence of N-acetylcysteine (NAC) and SNAC (56 and 560 µmol/L) and monitored at 234 nm.RESULTS: Animals in the control group developed moderate macro and microvesicular fatty changes in periportal area. SNAC-treated animals displayed only discrete histological alterations with absence of fatty changes and did not develop liver steatosis. The absence of NAFLD in the SNAC-treated group was positively correlated with a decrease in the concentration of LOOH in liver homogenate, compared to the control group (0.7±0.2 nmol/mg vs 3.2±0.4 nmol/mg protein, respectively, P<0.05), while serum levels of aminotransferases were unaltered. The ability of SNAC in preventing lipid peroxidation was confirmed in in vitro experiments using LA and LDL as model substrates.CONCLUSION: Oral administration of SNAC prevents the onset of NAFLD in Wistar rats fed with choline-deficient diet. This effect is correlated with the ability of SNAC to block the propagation of lipid peroxidation in vitro and in vitro.
机译:目的:评估S-亚硝基-N-乙酰半胱氨酸(SNAC)抑制脂质过氧化的潜力以及口服SNAC预防动物模型中非酒精性脂肪性肝病(NAFLD)的作用。 Wistar雄性大鼠通过胆碱缺乏饮食连续4周。将SNAC处理的动物(n = 6)(1.4 mg / kg /天SNAC,口服)与2个对照组进行比较:一个(n = 6)接受PBS溶液,另一(n = 6)接受NAC溶液(7毫克/千克/天)。组织学变量是关于宏观和微血管脂肪变化,其区域分布,坏死灶,门脉和静脉周围纤维化以及炎性浸润随区域分布的半定量。来自肝匀浆样品的LOOH通过HPLC定量。通过化学发光评估门静脉血浆中的硝酸盐水平。在不存在和存在SNAC(300 µmol / L)的情况下,将低密度脂蛋白(LDL)水性悬浮液(200 µg蛋白/ mL)与CuCl2(300 µmol / L)于37°C孵育15 h。通过荧光法评估LDL氧化的程度。在存在和不存在N-乙酰半胱氨酸(NAC)和SNAC(56和560μmol/ L)并在234 nm处监测。结果:对照组动物在门静脉周围区域出现了中度的大泡和微泡脂肪变化。 SNAC处理的动物仅表现出离散的组织学改变,没有脂肪变化,并且没有发展为肝脂肪变性。与对照组相比,SNAC治疗组中NAFLD的缺乏与肝脏匀浆中LOOH浓度的降低呈正相关(分别为0.7±0.2 nmol / mg和3.2±0.4 nmol / mg蛋白,P < 0.05),而血清氨基转移酶水平未改变。结论:以LA和LDL为模型底物的体外实验证实了SNAC具有预防脂质过氧化的能力。结论:口服SN​​AC可预防缺乏胆碱饮食的Wistar大鼠NAFLD的发生。该作用与SNAC在体外和体外阻断脂质过氧化的传播的能力有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号